Please login to the form below

Not currently logged in
Email:
Password:

NHS seeks 'solution creators' from within pharma

Health service is moving to a 'new era' of industry relations, says NHS England

IQVIA UK marketing access

The NHS is moving into a new era of relations with the pharmaceutical industry, according to NHS England.

But to make the most of this it needs ‘solution creators’ to come forward, commercial director of specialised commissioning Peter Huskinson (pictured, seated, centre) told a London meeting earlier this week.

Addressing IQVIA’s UK Market Access Summit he said: “Not withstanding the cold trade winds of Brexit, which I totally understand, I would content that we are moving into a new era in how we work and in what’s going on in pharma.

“Some of that you can see in national planning documents, and the contextual stuff that’s happening in the NHS, but also you can see it in what’s happening to medicine itself, with the technology.”

There has also been “a degree of convergence” among the people and bodies that work on assessing new medicines, he added, whether they be involved with NICE, the Cancer Drugs Fund or patient access schemes.

However, he was clear about what NHS England wanted from the pharmaceutical industry.

“Ultimately, we really are about working with ‘solution creators’ and not lobbyists. So if you, or anyone in your organisation thinks, that making a bigger stink about something will get you preferential treatment, I’ve got to tell you that my real equity goal is health benefits [for] every patient equally.

“The job of the healthcare system is to listen to the quietest voices, because they’re the people that often get left behind in care.”

However, a warning note about partnership working was sounded by another of the Summit’s speakers, Andrew White (picuted, seated, second from the right), who is medicines optimisation lead within the Greater Manchester Health and Social Care Partnership.

He said: “There’s a lot of people who have got a lot of bad history [and] there are a number of people with ‘scars on the back’.”

But he added: “That’s not to say that we can’t do great things.”

Article by
Dominic Tyer

16th March 2018

From: Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics